BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 25082556)

  • 1. Comparison of the effect of 18-month daily teriparatide administration on patients with rheumatoid arthritis and postmenopausal osteoporosis patients.
    Ebina K; Hashimoto J; Shi K; Kashii M; Hirao M; Yoshikawa H
    Osteoporos Int; 2014 Dec; 25(12):2755-65. PubMed ID: 25082556
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Usefulness of daily teriparatide treatment in elderly patients over 80 years of age.
    Niimi R; Kono T; Nishihara A; Hasegawa M; Matsumine A; Kono T; Sudo A
    Osteoporos Int; 2016 May; 27(5):1869-74. PubMed ID: 26759334
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of the effects of switching oral bisphosphonates to denosumab or daily teriparatide in patients with rheumatoid arthritis.
    Ebina K; Hirao M; Hashimoto J; Hagihara K; Kashii M; Kitaguchi K; Matsuoka H; Iwahashi T; Chijimatsu R; Yoshikawa H
    J Bone Miner Metab; 2018 Jul; 36(4):478-487. PubMed ID: 28766140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of daily teriparatide treatment for osteoporosis in men.
    Niimi R; Kono T; Nishihara A; Hasegawa M; Matsumine A; Kono T; Sudo A
    Osteoporos Int; 2015 Apr; 26(4):1303-9. PubMed ID: 25567777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of morning vs. evening teriparatide injection on bone mineral density and bone turnover markers in postmenopausal osteoporosis.
    Michalska D; Luchavova M; Zikan V; Raska I; Kubena AA; Stepan JJ
    Osteoporos Int; 2012 Dec; 23(12):2885-91. PubMed ID: 22426952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early changes in biochemical markers of bone turnover and their relationship with bone mineral density changes after 24 months of treatment with teriparatide.
    Blumsohn A; Marin F; Nickelsen T; Brixen K; Sigurdsson G; González de la Vera J; Boonen S; Liu-Léage S; Barker C; Eastell R;
    Osteoporos Int; 2011 Jun; 22(6):1935-46. PubMed ID: 20938767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An algorithm using the early changes in PINP to predict the future BMD response for patients treated with daily teriparatide.
    Niimi R; Kono T; Nishihara A; Hasegawa M; Matsumine A; Nakamura T; Kono T; Sudo A
    Osteoporos Int; 2014 Jan; 25(1):377-84. PubMed ID: 23812597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Teriparatide Treatment on Circulating Periostin and Its Relationship to Regulators of Bone Formation and BMD in Postmenopausal Women With Osteoporosis.
    Gossiel F; Scott JR; Paggiosi MA; Naylor KE; McCloskey EV; Peel NFA; Walsh JS; Eastell R
    J Clin Endocrinol Metab; 2018 Apr; 103(4):1302-1309. PubMed ID: 29365099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of switching weekly alendronate or risedronate to monthly minodronate in patients with rheumatoid arthritis: a 12-month prospective study.
    Ebina K; Noguchi T; Hirao M; Hashimoto J; Kaneshiro S; Yukioka M; Yoshikawa H
    Osteoporos Int; 2016 Jan; 27(1):351-9. PubMed ID: 26475289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluations of daily teriparatide using finite-element analysis over 12 months in rheumatoid arthritis patients.
    Ono K; Ohashi S; Oka H; Kadono Y; Yasui T; Matsumoto T; Omata Y; Tanaka S
    J Bone Miner Metab; 2021 Mar; 39(2):270-277. PubMed ID: 32886175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of switching oral bisphosphonates to denosumab or daily teriparatide on the progression of radiographic joint destruction in patients with biologic-naïve rheumatoid arthritis.
    Ebina K; Hirao M; Hashimoto J; Matsuoka H; Iwahashi T; Chijimatsu R; Etani Y; Okamura G; Miyama A; Yoshikawa H
    Osteoporos Int; 2018 Jul; 29(7):1627-1636. PubMed ID: 29574517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Daily or Cyclical Teriparatide Treatment in Women With Osteoporosis on no Prior Therapy and Women on Alendronate.
    Cosman F; Nieves JW; Zion M; Garrett P; Neubort S; Dempster D; Lindsay R
    J Clin Endocrinol Metab; 2015 Jul; 100(7):2769-76. PubMed ID: 25961136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women--the six-month effect of risedronate and teriparatide.
    Polyzos SA; Anastasilakis AD; Bratengeier C; Woloszczuk W; Papatheodorou A; Terpos E
    Osteoporos Int; 2012 Mar; 23(3):1171-6. PubMed ID: 21305266
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histomorphometric changes by teriparatide in alendronate-pretreated women with osteoporosis.
    Stepan JJ; Burr DB; Li J; Ma YL; Petto H; Sipos A; Dobnig H; Fahrleitner-Pammer A; Michalská D; Pavo I
    Osteoporos Int; 2010 Dec; 21(12):2027-36. PubMed ID: 20135094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of once-monthly minodronate versus risedronate in osteoporosis patients with rheumatoid arthritis: a 12-month randomized head-to-head comparison.
    Kumagai K; Harigane K; Kusayama Y; Tezuka T; Choe H; Inaba Y; Saito T
    Osteoporos Int; 2018 Jul; 29(7):1637-1642. PubMed ID: 29574518
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative effects of teriparatide and ibandronate on spine bone mineral density (BMD) and microarchitecture (TBS) in postmenopausal women with osteoporosis: a 2-year open-label study.
    Senn C; Günther B; Popp AW; Perrelet R; Hans D; Lippuner K
    Osteoporos Int; 2014 Jul; 25(7):1945-51. PubMed ID: 24760244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent.
    Cosman F; Wermers RA; Recknor C; Mauck KF; Xie L; Glass EV; Krege JH
    J Clin Endocrinol Metab; 2009 Oct; 94(10):3772-80. PubMed ID: 19584192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Denosumab significantly improves bone mineral density with or without bisphosphonate pre-treatment in osteoporosis with rheumatoid arthritis : Denosumab improves bone mineral density in osteoporosis with rheumatoid arthritis.
    Nakamura Y; Suzuki T; Kato H
    Arch Osteoporos; 2017 Sep; 12(1):80. PubMed ID: 28936606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Baseline serum PINP level is associated with the increase in hip bone mineral density seen with Romosozumab treatment in previously untreated women with osteoporosis.
    Kashii M; Kamatani T; Nagayama Y; Miyama A; Tsuboi H; Ebina K
    Osteoporos Int; 2023 Mar; 34(3):563-572. PubMed ID: 36585509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Relationship of BMD Increases Between the First 12 Months and the Latter 12 Months by Daily Teriparatide Treatment.
    Niimi R; Kono T; Nishihara A; Hasegawa M; Kono T; Sudo A
    Calcif Tissue Int; 2016 Sep; 99(3):282-8. PubMed ID: 27206528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.